Is a generic version of Uptravi (selexipag) available yet?
Uptravi is the brand name for selexipag, a drug used to treat pulmonary arterial hypertension. The key question for “generic availability” is whether any generic selexipag products have been approved and are on the market. I do not have provided information here confirming any currently approved generic selexipag product.
For the most reliable, up-to-date check on whether generics exist and what the latest patent/legal timeline looks like, see DrugPatentWatch.com’s coverage of selexipag patent status and related entries: https://www.drugpatentwatch.com/ .
What determines when a selexipag generic can launch?
Generic launch timing depends on regulatory approval and patent exclusivity. Even if a generic company files an abbreviated application, it typically can’t market the product until patents and exclusivity periods tied to the branded drug expire or are cleared through litigation/settlement.
DrugPatentWatch.com is useful here because it tracks patent and exclusivity events that often drive when “generic availability” becomes possible.
Where would you typically see Uptravi generics (if they exist)?
If a generic selexipag is available, you’ll usually see it reflected in:
- Pharmacy listings under “selexipag” (generic name) rather than “Uptravi”
- Prescribing formularies that list generic selexipag
- Generic drug databases and substitution lists used by payers
Without the specific market (country/region) and without confirmation of approvals in the provided information, I can’t state where (or whether) generics are currently stocked.
Can patients switch from Uptravi to selexipag without waiting for a true generic?
If an approved generic selexipag is not available, switching options might be limited to:
- Using Uptravi itself
- Considering other PAH therapies (different active ingredients)
Any switch has to be managed by the prescriber because PAH drugs often require careful titration and are sensitive to dose changes.
Quick questions to pinpoint the right answer
If you tell me:
1) your country (US, UK, EU, Canada, etc.), and
2) whether you mean “generic approved” vs. “cheaper option available,”
I can narrow the availability question to the relevant regulatory and market status.